Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1991 Sep;59(9):2922–2928. doi: 10.1128/iai.59.9.2922-2928.1991

Live vaccine strain of Francisella tularensis: infection and immunity in mice.

A H Fortier 1, M V Slayter 1, R Ziemba 1, M S Meltzer 1, C A Nacy 1
PMCID: PMC258114  PMID: 1879918

Abstract

The live vaccine strain (LVS) of Francisella tularensis caused lethal disease in several mouse strains. Lethality depended upon the dose and route of inoculation. The lethal dose for 50% of the mice (LD50) in four of six mouse strains (A/J, BALB/cHSD, C3H/HeNHSD, and SWR/J) given an intraperitoneal (i.p.) inoculation was less than 10 CFU. For the other two strains tested, C3H/HeJ and C57BL/6J, the i.p. log LD50 was 1.5 and 2.7, respectively. Similar susceptibility was observed in mice inoculated by intravenous (i.v.) and intranasal (i.n.) routes: in all cases the LD50 was less than 1,000 CFU. Regardless of the inoculation route (i.p., i.v., or i.n.), bacteria were isolated from spleen, liver, and lungs within 3 days of introduction of bacteria; numbers of bacteria increased in these infected organs over 5 days. In contrast to the other routes of inoculation, mice injected with LVS intradermally (i.d.) survived infection: the LD50 of LVS by this route was much greater than 10(5) CFU. This difference in susceptibility was not due solely to local effects at the dermal site of inoculation, since bacteria were isolated from the spleen, liver, and lungs within 3 days by this route as well. The i.d.-infected mice were immune to an otherwise lethal i.p. challenge with as many as 10(4) CFU, and immunity could be transferred with either serum, whole spleen cells, or nonadherent spleen cells (but not Ig+ cells). A variety of infectious agents induce different disease syndromes depending on the route of entry. Francisella LVS infection in mice provides a model system for analysis of locally induced protective effector mechanisms.

Full text

PDF
2922

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anthony L. S., Kongshavn P. A. Experimental murine tularemia caused by Francisella tularensis, live vaccine strain: a model of acquired cellular resistance. Microb Pathog. 1987 Jan;2(1):3–14. doi: 10.1016/0882-4010(87)90110-0. [DOI] [PubMed] [Google Scholar]
  2. Baker C. N., Hollis D. G., Thornsberry C. Antimicrobial susceptibility testing of Francisella tularensis with a modified Mueller-Hinton broth. J Clin Microbiol. 1985 Aug;22(2):212–215. doi: 10.1128/jcm.22.2.212-215.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bluestone J. A., Pardoll D., Sharrow S. O., Fowlkes B. J. Characterization of murine thymocytes with CD3-associated T-cell receptor structures. Nature. 1987 Mar 5;326(6108):82–84. doi: 10.1038/326082a0. [DOI] [PubMed] [Google Scholar]
  4. Burke D. S. Immunization against tularemia: analysis of the effectiveness of live Francisella tularensis vaccine in prevention of laboratory-acquired tularemia. J Infect Dis. 1977 Jan;135(1):55–60. doi: 10.1093/infdis/135.1.55. [DOI] [PubMed] [Google Scholar]
  5. Cross A. S., Sadoff J. C., Kelly N., Bernton E., Gemski P. Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection. J Exp Med. 1989 Jun 1;169(6):2021–2027. doi: 10.1084/jem.169.6.2021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. EIGELSBACH H. T., DOWNS C. M. Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J Immunol. 1961 Oct;87:415–425. [PubMed] [Google Scholar]
  7. Eigelsbach H. T., Hunter D. H., Janssen W. A., Dangerfield H. G., Rabinowitz S. G. Murine model for study of cell-mediated immunity: protection against death from fully virulent Francisella tularensis infection. Infect Immun. 1975 Nov;12(5):999–1005. doi: 10.1128/iai.12.5.999-1005.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. GOLD H. Anthrax; a report of one hundred seventeen cases. AMA Arch Intern Med. 1955 Sep;96(3):387–396. doi: 10.1001/archinte.1955.00250140109012. [DOI] [PubMed] [Google Scholar]
  9. Janis E. M., Kaufmann S. H., Schwartz R. H., Pardoll D. M. Activation of gamma delta T cells in the primary immune response to Mycobacterium tuberculosis. Science. 1989 May 12;244(4905):713–716. doi: 10.1126/science.2524098. [DOI] [PubMed] [Google Scholar]
  10. Koning F., Stingl G., Yokoyama W. M., Yamada H., Maloy W. L., Tschachler E., Shevach E. M., Coligan J. E. Identification of a T3-associated gamma delta T cell receptor on Thy-1+ dendritic epidermal Cell lines. Science. 1987 May 15;236(4803):834–837. doi: 10.1126/science.2883729. [DOI] [PubMed] [Google Scholar]
  11. Matis L. A., Cron R., Bluestone J. A. Major histocompatibility complex-linked specificity of gamma delta receptor-bearing T lymphocytes. Nature. 1987 Nov 19;330(6145):262–264. doi: 10.1038/330262a0. [DOI] [PubMed] [Google Scholar]
  12. McCrumb F. R. AEROSOL INFECTION OF MAN WITH PASTEURELLA TULARENSIS. Bacteriol Rev. 1961 Sep;25(3):262–267. doi: 10.1128/br.25.3.262-267.1961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Moingeon P., Jitsukawa S., Faure F., Troalen F., Triebel F., Graziani M., Forestier F., Bellet D., Bohuon C., Hercend T. A gamma-chain complex forms a functional receptor on cloned human lymphocytes with natural killer-like activity. Nature. 1987 Feb 19;325(6106):723–726. doi: 10.1038/325723a0. [DOI] [PubMed] [Google Scholar]
  14. O'Brien R. L., Happ M. P., Dallas A., Palmer E., Kubo R., Born W. K. Stimulation of a major subset of lymphocytes expressing T cell receptor gamma delta by an antigen derived from Mycobacterium tuberculosis. Cell. 1989 May 19;57(4):667–674. doi: 10.1016/0092-8674(89)90135-9. [DOI] [PubMed] [Google Scholar]
  15. Park C. H., Poretz D. M., Goldenberg R. Erysipelothrix endocarditis with cutaneous lesion. South Med J. 1976 Aug;69(8):1101–1103. [PubMed] [Google Scholar]
  16. THORPE B. D., MARCUS S. PHAGOCYTOSIS AND INTRACELLULAR FATE OF PASTEURELLA TULARENSIS. 3. IN VIVO STUDIES WITH PASSIVELY TRANSFERRED CELLS AND SERA. J Immunol. 1965 Apr;94:578–585. [PubMed] [Google Scholar]
  17. TIGERTT W. D. Soviet viable Pasteurella tularensis vaccines. A review of selected articles. Bacteriol Rev. 1962 Sep;26:354–373. doi: 10.1128/br.26.3.354-373.1962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Tärnvik A. Nature of protective immunity to Francisella tularensis. Rev Infect Dis. 1989 May-Jun;11(3):440–451. [PubMed] [Google Scholar]
  19. Young E. J. Human brucellosis. Rev Infect Dis. 1983 Sep-Oct;5(5):821–842. doi: 10.1093/clinids/5.5.821. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES